Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Completed · Phase 2

Conditions studied: Acute Myeloid Leukemia, Myelodysplastic Syndrome

In brief

The purpose of this study is to find out how safe and effective the combination of Mylotarg in combination with cytarabine is in treating patients with Acute Myeloid Leukemia and advanced Myelodysplastic Syndrome over the age of 60 years.

Key facts

Study ID

NCT00195000

Run by

Weill Medical College of Cornell University

People needed

43

Starts

2003-05-01

Expected to finish

2008-02-01

Last updated by the study team

2013-06-19

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Histologic diagnosis of AML or advanced MDS
• No prior cytotoxic treatment for AML. (patients may have been treated with prior biologic therapy) Patients with MDS or AML that has evolved from MDS, could have received prior low-dose cytotoxic therapy (i.e. azacytidine or low-dose ara-C).

You may not qualify if…

• Uncontrolled or severe cardiovascular disease or pulmonary disease

Where it is running

• Weill Medcial College of Cornell University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.